

The evidence digest collates recently released reports and evidence – provision of these links does not imply endorsement nor recommendation.

Post-acute SARS-CoV-2 infection outcomes in children, Paxlovid, Omicron-specific boosters

Peer reviewed journals featured:

- A systematic review on post-acute SARS-CoV-2 infection health outcomes in children [here](#)
- A narrative review on multisystem inflammatory syndrome in children and in neonates [here](#)
- Observational studies on:
 - COVID-19 mRNA vaccine safety among children aged 6 months–5 years in the US [here](#)
 - Long-term cardiac pathology in individuals with mild initial COVID-19 illness [here](#)
 - A machine learning analysis of COVID-19 mental health data [here](#)
 - Vaccination-associated mucosal antibody responses in previously infected people [here](#)
 - Epidemiology of respiratory syncytial virus in children younger than 5 years in England [here](#) and associated commentary [here](#)
- An editorial on the UK public inquiry on COVID-19 [here](#)
- Commentary on:
 - Narratives, counter narratives, and social dramas about the spread of COVID-19 [here](#)
 - UK's COVID-19 policy for children and schools [here](#)
 - British Society of Gastroenterology interim framework for addressing the COVID-19-related backlog in inflammatory bowel disease colorectal cancer surveillance [here](#)

Letters and correspondence discussed:

- Effects of vaccination and previous infection on Omicron infections in children [here](#)
- Durability of booster mRNA vaccine against Omicron BA.2.12.1, BA.4, and BA.5 subvariants [here](#)
- Nirmatrelvir–ritonavir (Paxlovid) and viral load rebound in COVID-19 [here](#) and [here](#)
- Efficacy of antiviral agents against the Omicron subvariant BA.2.75 [here](#)
- COVID-19 vaccine effectiveness and community prevalence of Alpha, Delta, and Omicron variants in patients with cirrhosis [here](#)
- Excess years of potential life lost in people with cirrhosis during COVID-19 [here](#)
- Orphanhood and caregiver loss among children based on new global excess death estimates [here](#)
- Protecting older people during COVID-19 [here](#)

Pre-peer review articles featured:

- Nirmatrelvir-ritonavir (Paxlovid) and molnupiravir in the treatment of mild/moderate COVID-19 [here](#)
- Effectiveness of COVID-19 vaccines against severe disease with Omicron BA.4 and BA.5 [here](#)
- Real-World COVID-19 vaccine protection rates against infection in the Delta and Omicron eras [here](#)
- Persistent somatic symptoms are key to individual illness perception at 1 year after COVID-19 [here](#)
- The prevalence of SARS-CoV-2 infection and long COVID in US adults during the BA.5 surge [here](#)
- Resistance of Omicron subvariant BA.4.6 to antibody neutralisation [here](#)
- Comparison of influenza and COVID-19 hospitalisations in British Columbia, Canada [here](#)
- Mucosal immunity and antibody anergy in COVID-exposed Covishield vaccinees [here](#)

Guidance and reports

- The World Health Organization published its weekly COVID-19 epidemiological report [here](#)

News and blogs

- New Omicron-specific vaccines offer similar protection to existing boosters [here](#)
- US and Canada to roll out the first Omicron specific boosters within days [here](#)
- How nasal-spray vaccines could change the pandemic [here](#)
- Lots of long COVID treatment leads, but few are proven [here](#)

[Click here](#) to subscribe to, or unsubscribe from, the evidence digest.

Living Evidence Tables

Living Evidence tables are up-to-date summaries of emerging evidence. Tables are available on SARS-CoV-2 [vaccines](#), and [variants](#) of concern, and [post-acute sequelae of COVID-19 \(long COVID\)](#).